In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Link Healthcare Pte Ltd.

http://www.linkhealthcare.co/

Latest From Link Healthcare Pte Ltd.

Clinigen Takes Aim At Unlicensed-To-Licensed Strategy With Quantum Buy

Extending its business in continental Europe, in niche generics and in the further development of unlicensed medicines are some of the drivers of Clinigen's latest proposed acquisition.

M & A Companies

Venture Funding Deals, November 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced September through October 2015.

BioPharmaceutical Medical Device

Pharmalink readies for PhIII on 'astonishing' glomerulonephritis data

Pharmalink of Sweden is basking in the "astonishingly good" Phase IIb data of Nefecon, its oral modified-release capsule of budesonide, in the treatment of primary IgA nephropathy – the most common form of glomerulonephritis. The NEFIGEN trial met its primary endpoint at a planned interim analysis and has been stopped early with respect to statistical analysis of the endpoint.

Gynecology & Urology Orthopedics

Pharmalink wins US orphan designation for Busulipo

Pharmalink, a Swedish specialty company, has received orphan drug designation from the US FDA for its transplant conditioning agent Busulipo (busulfan), which the company plans to file in late 2014.

See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Services
  • Other Names / Subsidiaries
    • LINK Pharma
    • LINK Medical Technologies
UsernamePublicRestriction

Register